Access to medically appropriate prescription drugs for people living with kidney disease must be preserved amid federal efforts to address the rising cost of prescription drugs. People with chronic kidney disease, kidney failure and kidney transplants rely on prescription drugs to manage their kidney disease and comorbidities. People need access to medically-appropriate prescription drugs that are effective and right for their individual situation, and they must be able to afford them.
To protect patient access to needed medications, avoid disruptions to stable drug regimens, and support lower prescription drug costs for patients, AKF supports:
- Policies that would result in lower drug costs and lower out-of-pocket costs for patients, particularly a restructuring of the Part D benefit that creates a true out-of-pocket cap for beneficiaries with a smoothing mechanism. We also support policies that protect a patient's ability to use drug copay coupons, discount cards, charitable assistance and other assistance to afford needed medications, and to have that assistance count towards their annual deductible and out-of-pocket spending cap.
- Efforts that encourage the introduction and availability of generic prescription drugs and biosimilars, while maintaining effective safeguards to ensure that patients for whom generic substitution is not medically appropriate still have access to branded drugs that are part of their stable drug regimen. AKF supports maintaining patient access to prescription drugs in the Medicare Part D program as it relates to the six categories and classes of drugs of clinical concern (the six protected classes), which includes immunosuppressive drugs for treatment of transplant rejection.
Take action on current issues
Keeping policymakers informed is critical in the fight against kidney disease. Add your voice to thousands of other voices in our Advocacy Network and help us make a difference!
Please email your members of Congress today and let them know that you are a kidney voter who urges them to take decisive action to help kidney patients.
Please contact your U.S. Representative and U.S. Senators to ask them to cosponsor the Living Donor Protection Act that will ensure that individuals who give the gift of life are protected from discrimination and are encouraged to help those in desperate need.
Medigap, or Medicare Supplement insurance, is private insurance available to Medicare beneficiaries to cover costs that Medicare does not cover.
This bill is a crucial first step in addressing our nation's growing need to prevent and address kidney disease. Please contact your U.S. Representative today and ask them to cosponsor this important piece of legislation.